journal article·2024-07-31

Engineering Magnetic Extracellular Vesicles Mimetics for Enhanced Targeting Chemodynamic Therapy to Overcome Ovary Cancer

Shuai Wang, Yinghua Mao, Shu Rong, Guangquan Liu, Yongping Cao, Zhan Yang, Huanhuan Yu, Xinrui Zhang, Hongyue Fang, Zhipeng Cai, Yonghong Chen, Hao Huang, Hong Li

ACS Applied Materials & Interfaces· Volume 16· Issue 30
Publisher page

Abstract

Chemodynamic therapy (CDT), employing metal ions to transform endogenous H 2 O 2 into lethal hydroxyl radicals ( • OH), has emerged as an effective approach for tumor treatment. Yet, its efficacy is diminished by glutathione (GSH), commonly overexpressed in tumors. Herein, a breakthrough strategy involving extracellular vesicle (EV) mimetic nanovesicles (NVs) encapsulating iron oxide nanoparticles (IONPs) and β-Lapachone (Lapa) was developed to amplify intracellular oxidative stress. The combination, NV-IONP-Lapa, created through a serial extrusion from ovarian epithelial cells showed excellent biocompatibility and leveraged magnetic guidance to enhance endocytosis in ovarian cancer cells, resulting in selective H 2 O 2 generation through Lapa catalysis by NADPH quinone oxidoreductase 1 (NQO1). Meanwhile, the iron released from IONPs ionization under acidic conditions triggered the conversion of H 2 O 2 into • OH by the Fenton reaction. Additionally, the catalysis process of Lapa eliminated GSH in tumor, further amplifying oxidative stress. The designed NV-IONP-Lapa demonstrated exceptional tumor targeting, facilitating MR imaging, and enhanced tumor suppression without significant side effects. This study presents a promising NV-based drug delivery system for exploiting CDT against NQO1-overexpressing tumors by augmenting intratumoral oxidative stress.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Diseases Prevention and Control of Eastern Theater, Nanjing 210002, China

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China

Department of Gynecology, Women’s Hospital of Nanjing Medical University (Nanjing Maternity and Child Health Care Hospital), Nanjing 210001, China

Department of Clinical Pharmacy, General Hospital of Eastern Theater Command, Nanjing 210002, China

Department of Third Outpatient, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing 210029, China

Department of Obstetrics and Gynecology, Foshan Fosun Chancheng Hospital, Foshan 528000, China

Funding

National Natural Science Foundation of China

References (59)

Show source-provided references
1. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
2. 10.1016/j.semcdb.2017.05.02310.1016/j.semcdb.2017.05.023 ↗
3. 10.1016/j.molcel.2023.11.00110.1016/j.molcel.2023.11.001 ↗
4. 10.1038/s41580-020-0230-310.1038/s41580-020-0230-3 ↗
5. 10.1038/nrd400210.1038/nrd4002 ↗
6. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
7. 10.1021/acsami.3c0379210.1021/acsami.3c03792 ↗
8. 10.1002/adma.20200689210.1002/adma.202006892 ↗
9. 10.1016/j.actbio.2023.01.02210.1016/j.actbio.2023.01.022 ↗
10. 10.1021/acsnano.3c0327910.1021/acsnano.3c03279 ↗
11. 10.1021/acsami.3c0403810.1021/acsami.3c04038 ↗
12. 10.1002/smll.20210386810.1002/smll.202103868 ↗
13. 10.1021/acsami.4c0085310.1021/acsami.4c00853 ↗
14. 10.1021/acsami.9b0932310.1021/acsami.9b09323 ↗
15. 10.1021/acsami.3c1256010.1021/acsami.3c12560 ↗
16. 10.1038/s41467-017-00424-810.1038/s41467-017-00424-8 ↗
17. 10.1021/acsnano.3c0296410.1021/acsnano.3c02964 ↗
18. 10.1021/acsami.4c0010910.1021/acsami.4c00109 ↗
19. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
20. 10.1021/acsnano.8b0504210.1021/acsnano.8b05042 ↗
21. 10.1186/s12951-023-02287-210.1186/s12951-023-02287-2 ↗
22. 10.1016/j.jconrel.2014.12.02710.1016/j.jconrel.2014.12.027 ↗
23. 10.1073/pnas.230686812010.1073/pnas.2306868120 ↗
24. 10.3390/ijms2409783910.3390/ijms24097839 ↗
25. 10.1016/j.biomaterials.2022.12168710.1016/j.biomaterials.2022.121687 ↗
26. 10.1016/j.jconrel.2022.05.03110.1016/j.jconrel.2022.05.031 ↗
27. 10.1016/j.freeradbiomed.2017.07.01810.1016/j.freeradbiomed.2017.07.018 ↗
28. 10.1021/acsnano.3c0240110.1021/acsnano.3c02401 ↗
29. 10.1021/jacs.9b1075510.1021/jacs.9b10755 ↗
30. 10.1016/j.actbio.2022.12.04110.1016/j.actbio.2022.12.041 ↗
31. 10.1021/acsnano.8b0908210.1021/acsnano.8b09082 ↗
32. 10.1016/j.jconrel.2021.04.00710.1016/j.jconrel.2021.04.007 ↗
33. 10.1002/advs.20230257910.1002/advs.202302579 ↗
34. 10.1002/adhm.20220291110.1002/adhm.202202911 ↗
35. 10.1016/j.jconrel.2022.12.02710.1016/j.jconrel.2022.12.027 ↗
36. 10.1016/j.medj.2024.03.01210.1016/j.medj.2024.03.012 ↗
37. 10.1016/j.biomaterials.2022.12138410.1016/j.biomaterials.2022.121384 ↗
38. 10.1021/acsami.3c1683910.1021/acsami.3c16839 ↗
39. 10.1002/adfm.20200832610.1002/adfm.202008326 ↗
40. 10.1021/acs.nanolett.8b0181610.1021/acs.nanolett.8b01816 ↗
41. 10.1016/j.drup.2023.10100710.1016/j.drup.2023.101007 ↗
42. 10.2147/IJN.S18545810.2147/IJN.S185458 ↗
43. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
44. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
45. 10.1002/adfm.20200832610.1002/adfm.202008326 ↗
46. 10.1021/cr068445e10.1021/cr068445e ↗
47. 10.1016/j.biomaterials.2016.08.03910.1016/j.biomaterials.2016.08.039 ↗
48. 10.1016/j.foodchem.2017.07.07610.1016/j.foodchem.2017.07.076 ↗
49. 10.1016/j.addr.2021.05.01110.1016/j.addr.2021.05.011 ↗
50. 10.1002/adma.20220105410.1002/adma.202201054 ↗
51. 10.1021/acsami.9b1663710.1021/acsami.9b16637 ↗
52. 10.1002/adhm.20227011710.1002/adhm.202270117 ↗
53. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
54. 10.1002/adhm.20230034910.1002/adhm.202300349 ↗
55. 10.1016/j.ijpx.2024.10023110.1016/j.ijpx.2024.100231 ↗
56. 10.3390/pharmaceutics1412282210.3390/pharmaceutics14122822 ↗
57. 10.1039/D1NH00637A10.1039/D1NH00637A ↗
58. 10.1021/acsami.6b0733810.1021/acsami.6b07338 ↗
59. 10.2217/nnm-2023-028910.2217/nnm-2023-0289 ↗